The 10-second takeaway
For the quarter ended Dec. 31 (Q1), AmerisourceBergen beat slightly on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly and GAAP earnings per share dropped.
Gross margins were steady, operating margins were steady, and net margins were steady.
AmerisourceBergen reported revenue of $20.36 billion. The 13 analysts polled by S&P Capital IQ anticipated revenue of $19.99 billion. Sales were 2.4% higher than the prior-year quarter's $19.89 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.62. The earnings estimates compiled by S&P Capital IQ averaged $0.63 per share on the same basis. GAAP EPS of $0.62 for Q1 were 8.8% higher than the prior-year quarter's $0.57 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 2.9%, about the same as the prior-year quarter. Operating margin was 1.4%, about the same as the prior-year quarter. Net margin was 0.8%, about the same as the prior-year quarter.
Next quarter's average estimate for revenue is $20.05 billion. On the bottom line, the average EPS estimate is $0.81.
Next year's average estimate for revenue is $80.88 billion. The average EPS estimate is $2.81.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmerisourceBergen is outperform, with an average price target of $45.70.
If you're interested in health-care stocks like AmerisourceBergen, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add AmerisourceBergen to My Watchlist.